PD31-03 IMPAIRMENT FREE SURVIVAL: A RELEVANT CLINICAL ENDPOINT FOR BLADDER CANCER PATIENTS UNDERGOING CYSTECTOMY
Cheryl Lee(Agency for Science, Technology and Research), Alon Z. Weizer(University of Michigan), Stephanie Daignault‐Newton(Ann Arbor Center for Independent Living), Todd M. Morgan(University of Michigan), Pearl Lee(Cancer Research Institute), Michael J. Englesbe(University of Michigan), Michael Termanjian(Ann Arbor Center for Independent Living), Khaled Hafez(University of Michigan), Brent K. Hollenbeck(University of Michigan), Jeffrey S. Montgomery(Ann Arbor Center for Independent Living), Linda Drnek(Ann Arbor Center for Independent Living)
Cited by 0
Related Papers
What Is Trophoblast? A Combination of Criteria Define Human First-Trimester Trophoblast
|Stem Cell Reports|2016|308
Standardization of Radical Cystectomy and Pelvic Lymph Node Dissection for Bladder Cancer: A Collaborative Group Report
|The Journal of Urology|2004|293
Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
|European Urology|2012|257
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
|PubMed|2022|172
Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro‐ureterectomy
|British Journal of Urology|2013|165